Compounds for the treatment of neurological disorders

Details Compounds for the treatment of neurological disorders Compounds for the treatment of neurological disorders

2005-11-30

2010-02-23

Padmanabhan, Sreeni (Department: 1617)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S518000, C548S530000, C548S527000, C514S365000, C514S423000

Reexamination Certificate

active

07667044

ABSTRACT:
The present invention relates to novel inhibitors of prolyl endopeptidase of formula 1in-line-formulae description="In-line Formulae" end="lead"?W—KCONH—X—CON—Y—CO—Z  (1)in-line-formulae description="In-line Formulae" end="tail"?wherein K, W, X, Y and Z are specified in the description.The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.

REFERENCES:
patent: 5547978 (1996-08-01), Christensen et al.
patent: 7371871 (2008-05-01), Schilling
patent: 7381537 (2008-06-01), Demuth
patent: 7462599 (2008-12-01), Schilling
patent: 2005/0171112 (2005-08-01), Schulz et al.
patent: 2007/0191366 (2007-08-01), Hoffmann
patent: 2008/0153892 (2008-06-01), Schilling
patent: 2008/0286810 (2008-11-01), Demuth
patent: 2009/0068699 (2009-03-01), Schilling
patent: 2009/0149394 (2009-06-01), Schilling
patent: 0 154 353 (1985-09-01), None
patent: 0 201 741 (1986-11-01), None
patent: WO 95/22327 (1995-08-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 03/040174 (2003-05-01), None
patent: WO 2004/098591 (2004-11-01), None
patent: WO 2005/075436 (2005-08-01), None
patent: WO 2005/103043 (2005-11-01), None
Database Beilstein; Data Accession Nos. 580461, 4016039 (XP002378930); vol. 642, 1961, pp. 133-140.
Database Beilstein; Data Accession Nos. 8498197, 8498907, 8507776, 8508303 (XP002378931); vol. 55, 1999, pp. 15001-15010.
Database Beilstein; Data Accession No. 8589072 (XP002378932); vol. 1, 2001, pp. 113-120.
Database Beilstein; Data Accession No. 9878605 (XP002378933); vol. 11, 2004, pp. 1806-1813.
Database Beilstein; Data Accession Nos. 9878207, 9878604 (XP002378934); vol. 16, 2004, pp. 2645-2652.
Database Beilstein; Data Accession No. 5913897 (XP002378935); vol. 34(2), 1993, pp. 211-214.
Database Beilstein; Data Accession No. 6678654 (XP002378936); vol. 35(4), 1994, pp. 591-594.
Database Beilstein; Data Accession No. 8528734 (XP002378937); vol. 10(1), 2000, pp. 45-48.
Database Beilstein; Data Accession No. 8462536 (XP002378938); vol. 117(5), 1996, pp. 986-992.
Joyeau, et al.; “Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptidase derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi”;Eur. J. Med. Chem.; 2000; 35: 257-266.
Ferraris, et al.; “Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors”;Bioorganic&Medicinal Chemistry Letters; 2004; 14: 5579-5583.
De Nanteuil, et al.; “Prolyl endopeptidase inhibitors: a new class of memory enhancing drugs”;Drugs of the Future; 1998; 23(2): 167-179.
Tsutsumi, et al.; “•-Ketothiazole Inhibitors of Prolyl Endopeptidase”;Bioorganic&Medicinal Chemistry Letters; 1994; 4(6): 831-834.
Tsutsumi, et al.; “Synthesis and Structure-Activity Relationships of Peptidyl alpha-Keto Heterocycles as Novel Inhibitors of Prolyl endopeptidase”;J. Med. Chem.; 1994; 37(21): 3492-3502.
Tsutsumi, et al.; “Prolyl Endopeptidase Inhibitors II. A peptidyl alpha-Keto Thiazole Derivative”;ACTA Cryst.; 1995; C51: 1925-1927.
International Search Report for Application No. PCT/EP2005/012765 date of completion May 4, 2006.

Affiliated with

Also associated with

Rating

Compounds for the treatment of neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of neurological disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4205709